AD743923

OFFICE OF NAVAL RESEARCH

Contract N00014-69-A-0385-0003

TECHNICAL REPORT NO. 6

Effect of Prostaglandin E_1 on the Pulmonary Vascular Response

to Endotoxin

Prepared by

E. G. Erdös

For Publication in

Proc. Soc. Exper. Biol. Med.

Department of Pharmacology
University of Oklahoma Health Sciences Center
College of Medicine, Oklahoma City, Oklahoma

D D C

RECEIVED

JUN 21 1972

RECEIVED

U3 B

May 31, 1972

DISTRIBUTION STATEMENT A

Approved for public release;
Distribution Unlimited

15

DOCUMENT CONTROL DATA - R & D

(Security classification of title, body of abstract and indexing annotation must be entered when the overall report is classified)

1. ORIGINATING ACTIVITY *(Corporate author)*	2a. REPORT SECURITY CLASSIFICATION
Medical Center Research & Development Office of the Univ. of Okla. Foundation, Inc., 800 Northeast 15th Street, Suite 500, Oklahoma City, Oklahoma 73104	2b. GROUP

3. REPORT TITLE

Effect of Prostaglandin E_1 on the Pulmonary Vascular Response to Endotoxin

4. DESCRIPTIVE NOTES *(Type of report and inclusive dates)*

Technical Report

5. AUTHOR(S) *(First name, middle initial, last name)*

K. Sorrells, E. G. Erdös and W. H. Massion

6. REPORT DATE	7a. TOTAL NO. OF PAGES	7b. NO. OF REFS
May 31, 1972	8 pages	26

8a. CONTRACT OR GRANT NO.	9a. ORIGINATOR'S REPORT NUMBER(S)
N00014-69-A-0385-0003	
b. PROJECT NO.	Technical Report No. 6
c.	9b. OTHER REPORT NO(S) *(Any other numbers that may be assigned this report)*
d.	

10. DISTRIBUTION STATEMENT

Distribution of this document is unlimited.

11. SUPPLEMENTARY NOTES	12. SPONSORING MILITARY ACTIVITY
	Office of Naval Research Arlington, Virginia

13. ABSTRACT

Endotoxin causes an increase in vascular resistance and the release of some lysosomal enzymes in the circulation of the isolated lobe of the dog lung perfused in situ. These effects of endotoxin were prevented by the administration of PGE_1. When PGE_1 was infused after endotoxin was given, the increase in the pulmonary perfusion pressure was greatly reduced. Thus similar to the previously tested anti-inflammatory drugs, PGE_1 can block some of the effects of endotoxin in the circulation.

DD FORM 1473 (PAGE 1)
1 NOV 65

S/N 0101-807-6811

Effect of Prostaglandin E_1 on the Pulmonary Vascular

Response to Endotoxin

K. Sorrells, E. G. Erdös and W. H. Massion

Departments of Pharmacology and Anesthesiology, University

of Oklahoma, School of Medicine, Oklahoma City, Oklahoma

II

Injection of endotoxin to dogs is usually followed by a preceptious drop in systemic arterial blood pressure, rise in portal venous pressure and by increase in resistance in some vascular beds, for example in the lung (1,2,3,4). It has been also indicated, that endotoxin may cause damage to tissues and the release of subcellular constituents such as lysosomal enzymes (5,6). The aggregation of platelets is also a frequently encountered symptom in septic and other forms of shock (7,8,9). Among the organs that are involved in shock, the lung has been frequently mentioned (10).

Because some prostaglandins can stabilize some cell membranes (11) through the accumulation of cyclic AMP (3'-5' adenosine monophosphate), inhibit platelet clumping (12) and are potent vasodilators (13), we tested the effects of prostaglandin E_1 (PGE_1) on the isolated lobe of the shocked lung perfused in situ.

MATERIALS AND METHODS

Six mongrel dogs weighing 15-30 kg were anesthetized with sodium pentobarbital, 30 mg/kg i.v. The thorax was opened through an intercostal space, the pulmonary artery and vein leading to and from the right lower and subsequently from the upper lobe were ligated and the circulation of the lobe was completely isolated from the rest of the lung, as previously described (14). Blood was collected in a venous reservoir and was pumped into an elevated arterial reservoir by a Sigma motor pump. From here the blood flowed by gravity into the isolated lung lobe. The height of the blood column in the venous reservoir, the pressure in the pulmonary artery and the systemic arterial blood pressure were recorded by Statham transducers connected to a Grass polygraph. In this perfusion system the flow through the lung was identical to the flow delivered from the Sigma motor pump as long as the

volume of the arterial reservoir did not change. Thus changes in pulmonary arterial pressure reflected proportional changes in the pulmonary vascular resistance.

PGE_1 (1 mg/ml) was dissolved in 95% ethanol. The compound was infused in saline in a concentration of 1 ug/ml at a rate of 0.95 ml per min in the pulmonary artery 10 min before endotoxin was administered. In control studies saline with the same amount of alcohol was given. Six mg of endotoxin (Escherichia coli, Difco) was dissolved in 2 ml of saline and added to the venous reservoir of the blood.

In each animal the lower and upper lobes of the left lung were isolated and perfused sequentially. One lobe received endotoxin and saline and was used as control, the other one was perfused with PGE_1 and endotoxin. Thus each animal served as its own control, since the sequence of the experimental and control studies was reversed repeatedly. The effect of endotoxin was expressed as % increase in pulmonary perfusion pressure (PPP).

Blood samples were taken at 0 time and 5-10 minutes after the administration of endotoxin. Proteins in plasma, were measured by the biuret method (15).

The activity of β-glucuronidase was assayed with phenolphthalein glucuronate substrate (16), and expressed as ug phenolphthalein released/hr per mg of serum protein. Acidic catheptic activity was determined with hemoglobin substrate (17), expressed as ug tyrosine released/hr per mg, and prolylcarboxypeptidase (PCP) with ^{14}C-1-dimethylamino-naphthyl-5-sulfonyl-(DNS)-Pro-Phe (18,19,20). This substrate was prepared by reacting ^{14}C-DNS.Cl

with Pro-Phe. The resulting radioactive and fluorescent substrate ^{14}C-DNS-Pro-Phe (3.9 nmole) was incubated with plasma (0.1 ml) at 37° in 0.1 ml 0.1 M acetate buffer of pH 4.5. Samples were taken after 5 hr of incubation and applied to silica coated glass microfiber sheets. Thin-layer chromatography was done in n-butanol:n-amyl alcohol:NH_4 OH (50:40:1) solvent (18). The fluorescent substrate and the product of its enzymic hydrolysis (^{14}C-DNS-Pro) were separated by thin-layer chromatography and localized under UV light. The spots were cut out from the sheets, placed in a vial containing a liquid scintillator and radioactivity was measured in a scintillation counter.

RESULTS

Infusion of endotoxin in the perfused lung lobe led to vasoconstriction as shown by the increase in the volume of blood in the arterial reservoir. Endotoxin increased the PPP by 62% ($\pm$ 6 S.E; Fig. 1). Prior infusion of a total of 9.5 ug PGE$_1$ blocked most of the increase in pressure (14% $\pm$ 5). In 2 animals PGE$_1$ was infused 10 min after the administration of endotoxin (Fig. 2). During the infusion of PGE$_1$ the increase in PPP was greatly reduced and the perfusion pressure returned almost to the pre-endotoxin level. When the infusion of PGE$_1$ was stopped, the pressure started to rise again.

The release of lysosomal enzymes in shock was also measured in the plasma collected from the perfused lobe. Administration of endotoxin raised the level of β-glucuronidase (P $<$ 0.05 by sequential analysis) and catheptic activity (P $<$ 0.001) significantly. This increase in lysosomal enzyme activity was essentially abolished by pretreatment with PGE$_1$ (Fig. 3).

In the blood perfusing the lobe PCP activity did not increase after shock. Administration of PGE_1 either had no influence on the level of this enzyme (Fig. 4). This ranged from 0.09 to 0.12 ($\pm$ 0.02) pmole/hr per mg of serum protein.

DISCUSSION

These studies showed that the administration of endotoxin increased the perfusion pressure of the lung lobe perfused in situ. There was a simultaneous increase in the activity of two lysosomal enzymes in the blood plasma of the isolated lobe. Both of these effects were abolished or greatly decreased by pretreatment with PGE_1. PGE_1 also lowered the elevated PPP when it was given after endotoxin administration. It is unlikely that the beneficial action of PGE_1 was due to the abolishment of platelet aggregation (12,21) known to be induced by endotoxin (8). Recent studies indicated that endotoxin increased pulmonary vascular resistance in the isolated lobe of the lung, even when it was perfused with blood depleted of platelets. The effect of endotoxin on the pulmonary vascular resistance does not depend on the presence of platelets in the perfusate (22). Thus in this preparation PGE_1 acted as a vasodilator and as a lysosomal membrane stabilizer. Recently, Weissman et al (11) indicated that PGE_1 can prevent the release of lysosomal enzymes from leucocytes in vitro by increasing the concentration of intracellular cyclic AMP. A recently published abstract attributed the in vivo beneficial effects of PGE_1 in endotoxin shock to suppression of the release of lysosomal enzymes in the dog (23).

In contrast to the two other lysosomal enzymes we studied, there was no increase in PCP activity either in the perfusate collected from the lung of shocked dogs or in the dogs which received PGE_1 in addition to endotoxin. PCP is present in the lysosomal fraction of the homogenized kidney (18) and granulocytes (19). It is an enzyme that cleaves peptide bonds of

penultimate proline with C-terminal amino acids (18). One naturally
occurring substrate of this enzyme is angiotensin II, which is rapidly
inactivated by PCP by the hydrolysis of the terminal Pro^7-Phe^8 bond.
In the present experiments the circulation of the isolated lobe was com-
pletely separated from the rest of the circulation. Earlier studies showed
that during perfusion the number of leucocytes and platelets decreased
greatly in the blood perfusing the lobe (22), possibly because cells migrate
from the blood into the pulmonary tissue (24). If the source of PCP had
been depleted, an increase in the enzyme level after endotoxin administra-
tion could not be expected. Normally, PCP activity (18) is very low in
plasma, but it increases in the systemic circulation during septic shock
(20).

The two other lysosomal enzymes assayed, β-glucuronidase and the cathepsin
may come from tissues other than leucocytes.

Because of the clinical importance of septic shock, many drugs have been
tested in laboratory animals to combat this condition. For example, non-
steroidal anti-inflammatory agents blocked some of the effects of the
injection of endotoxin (2,3,4) or live E. coli micro-organisms (6) in dogs.
Anti-inflammatory drugs may also antagonize some prostaglandins by blocking
their release, biosynthesis and action on some smooth muscles (25). PGE_1
and anti-inflammatory drugs, however, can have a similar mode of action
because both can prevent the aggregation of platelets (21,26). Additional
similarity between the effects of PGE_1 and anti-inflammatory drugs was
                                here
provided/by showing that both types of compounds could block some of the
effects of endotoxin on the circulation.

SUMMARY

Endotoxin causes an increase in vascular resistance and the release of some lysosomal enzymes in the circulation of the isolated lobe of the dog lung perfused in situ. These effects of endotoxin were prevented by the administration of PGE_1. When PGE_1 was infused after endotoxin was given, the increase in the pulmonary perfusion pressure was greatly reduced. Thus similar to the previously tested anti-inflammatory drugs, PGE_1 can block some of the effects of endotoxin in the circulation.

LEGENDS TO THE FIGURES

Fig. 1. Administration of endotoxin in the isolated lobe of the dog lung increases perfusion pressure (PPP). (A.) This was greatly reduced by simultaneous administration of PGE_1; (B.) Vertical bars: $\pm$ 1 S.E. (n=6).

Fig. 2. Infusion of PGE_1 after endotoxin administration abolishes the effect of endotoxin.

Fig. 3. Catheptic and β-glucuronidase activities increased in the blood perfusing the isolated lobe after endotoxin administration. PGE_1 blocked the rise in the lysosomal enzyme level (n=5 cathepsin; n=6 β-glucuronidase).

Fig. 4. Endotoxin does not increase the prolylcarboxypeptidase activity in the blood perfusing the lobe. PGE_1 had no effect on this enzymic activity (n=6).

REFERENCES

1. Gilbert, R. P., Physiol. Rev. 40: 245 (1960).

2. Hinshaw, L. B., Solomon, L. A., Erdős, E. G., Reins, D. A., and Gunter, B. J., J. Pharmacol. Exper. Therap. 157: 665 (1967).

3. Erdős, E. G., Hinshaw, L. B., and Gill, C. C., Proc. Soc. Exper. Biol. 125: 916 (1967).

4. Massion, W. H., and Erdős, E. G., J. Okla. State Med. Assoc. 59: 467, (1966).

5. Janoff, A., Weissmann, G. W., Zweifach, B., and Thomas, L., J. Exp. Med. 116: 451 (1962).

6. Culp, J. R., Erdős, E. G., Hinshaw, L. B., and Holmes, D. D., Proc. Soc. Expl. Biol. Med. 137: 219 (1971).

7. Dale, H. H., and Kellaway, C. H., Royal Soc. Philosophical trans. B, 211: 372 (1922).

8. Hardaway, R. M. III, "Syndromes of Disseminated Intravascular Coagulation" p. 202. Thomas, Springfield, Illinois (1966).

9. Packham, M. A., Nishizawa, E. E., and Mustard, J. F., In "Chemical Biology of Inflammation" (J. C. Houck, B. K. Forscher, eds.), p. 171. Pergamon Press, Oxford (1968).

10. Goodman, J. R., Lim, R. C., Blaisdell, F. W., Hall, A. D., and Thomas, A. N., Am. J. Pathol. 52: 391 (1968).

11. Weissmann, G., Dukor, P., and Zurier, R. B., Nature New Biol. 231: 131 (1971).

12. Robison, G., Arnold, A., Cole, B., and Hartmann, R., N. Y. Acad. Sci. 180: 324 (1971).

13. Horton, E. W., and Main, I. H. M., Br. J. Pharmacol. Chemother. 21: 182 (1963).

14. Kux, M., and Massion, W. H., Annals Surg. 173: 116 (1971).

15. Gornall, A. G., Bardawill, C. J., and David, M. M., J. Biol. Chem. 177: 751 (1949).

16. Fishman, W. H., In "Methods of Enzymatic Analysis" (H.-U. Bergmeyer, ed.), p. 869. Academic Press, New York (1963).

17. Anson, M. L., J. Gen. Physiol. 20: 565 (1936).

18. Yang, H. Y. T., Erdös, E. G., Chiang, T. S., Jenssen, T. A., and Rodgers, J. G., Biochem. Pharmacol. 19: 1201 (1970).

19. Sorrells, K., and Erdös, E. G., Fed. Proc. 30: 600 (1971).

20. Sorrells, K., and Erdös, E. G., "What are the Fundamental Mechanisms of Shock?" Symposium: Oklahoma City (Hinshaw, L. B. et al. eds.). Plenum Press. In Press. (1971) .

21. Hornstra, G., Europ. J. Pharmacol. 15: 343 (1971).

22. Kux, M, Coalson, F. F., Massion, W. H., and Guenter, C. A., Annals Surg. In press.

23. Glenn, T. M., Raflo, G. 1., Wangensteen, S. L., and Lefer, A. M., The Pharmacologist 13: 293 (1971).

24. Wilson, J. W., Ratliff, N. B., Hackel, D. B., Mikat, E., and Graham, T., In "Immunopathology of Inflammation" (B. K. Forscher and J. C. Houcke, eds.), p.183. Excerpta Medica, Amsterdam (1971).

25. Vane, J. R., Nature New Biol. 231: 232 (1971).

26. Glenn, E. M. and Sekhar, N. C., In ref. 17 p. 13.

Before -- A
After -- B
Endotoxin + Saline
Endotoxin + PGE$_1$

Catheptic Activity

ug/hr/mg

β-- Glucuronidase

Before—A, After—B
Endotoxin + Saline
Endotoxin + PGE$_1$

Y-axis: p mole/hr/mg

Values: 0, 0.05, 0.10, 0.15

Bar chart with y-axis labeled "PERCENT INCREASE IN PPP" marked at 0, 20, 40, 60. Bar A (Endotoxin + Saline) reaches approximately 61. Bar B (Endotoxin + PGE₁) reaches approximately 13.

Legend:
A – Endotoxin + Saline
B – Endotoxin + PGE$_1$